Furosemide Inhalation in Dyspnea of Mustard Gas Exposed Patients
Information source: Baqiyatallah Medical Sciences University
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Bronchiolitis
Intervention: furosemide (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: Baqiyatallah Medical Sciences University Official(s) and/or principal investigator(s):
Mostafa Ghanei, MD, Study Chair, Affiliation: Research Center of Chemical Injuries, Baqiyatallah Medical Science University, Tehran, Iran
Summary
to assess the efficacy of inhaled furosemide in mustard gas exposed patients with acute
respiratory failure
Clinical Details
Official title: Furosemide Inhalation in Dyspnea of Mustard Gas Exposed Patients: a Double-Blind Randomized Study
Study design: Supportive Care, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Crossover Assignment
Primary outcome: effect of furosemid inhalation on dyspnea
Eligibility
Minimum age: 32 Years.
Maximum age: 83 Years.
Gender(s): Male.
Criteria:
Inclusion Criteria:
- Patients with a history of exposure to sulfur mustard with a complaint of dyspnea
Exclusion Criteria:
- A contraindication for furosemide use;
- An accompanying disease in which other drugs effective for dyspnea were used
Locations and Contacts
RCCI, Tehran, Iran, Islamic Republic of
Additional Information
Last updated: August 7, 2007
|
